Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
about
Advances and challenges in malaria vaccine developmentEuropean Vaccine Initiative: lessons from developing malaria vaccinesA review of malaria vaccine clinical projects based on the WHO rainbow tablePreclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxThe clinical development process for a novel preventive vaccine: An overviewMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaVaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaquesProduction, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic VariationHumoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adultsTransgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adultsHigh antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus modelPhase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.Juxtamembrane shedding of Plasmodium falciparum AMA1 is sequence independent and essential, and helps evade invasion-inhibitory antibodiesPhase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunizedBlood stage vaccines for Plasmodium falciparum: current status and the way forward.Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirusLong-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humansRecombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.Analysis of the dose-dependent stage-specific in vitro efficacy of a multi-stage malaria vaccine candidate cocktail.Progress and prospects for blood-stage malaria vaccinesPhase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in BandiagaraAnti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study.Approaches to malaria vaccine development using the retrospectroscope.Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
P2860
Q21032463-93A2386B-BA02-4E31-99F3-98B7734F3BFCQ21032652-6BDDCD1B-5EB8-4C5E-BB3B-CF0C77FB6D9EQ21034112-28AD9BF2-D5AB-4C62-9515-26ECE05E5D13Q24273364-D07E80E1-984A-4DDC-9503-34CDCA396B1CQ26770871-37E81F07-98FE-4D9D-8F97-CAAFC5454D90Q26772878-A98C163A-199E-4C66-9970-5EA6E930B0F3Q27336448-948E9412-4F45-4E0F-B042-2A560F883DEDQ28554439-BDE1E946-E170-4C3D-AC32-65817913D8B1Q28727698-01BC0F0E-40C7-41E3-B1AD-CE07381A5455Q28743564-9F7211E4-A8C8-4940-8E36-4448B986D7DCQ28744696-BB3C716C-C53C-4098-B456-ABFB59C24B16Q28749215-86EEBAC3-8406-40D1-9BC3-FB3A6E25A6ACQ28749979-44E4C1DA-6C30-415A-92AE-4C0C169A77AFQ33434412-44F102BE-E0B8-477A-A4F3-79F7C8FE9483Q33654911-0085C837-41D3-46F0-A66F-98CDB9D5402FQ33762869-8418E770-9812-4259-A98F-4F2CBFD3F8E4Q33939405-E7985741-3AA3-492A-9864-5D620BCE3F75Q33974904-5EBB2113-80A9-43B7-BC34-A09A2C9D273FQ34109788-E2D25DEE-DCCF-4F9E-97A9-F93179E9CF71Q34546201-D2775D2A-5975-45C1-A2F4-73F4574C0241Q34600955-67413B34-5726-435C-A33F-03056DD00535Q34612788-53956A8F-C7AE-46DD-B537-1C27A5F90C01Q34663978-8F19B880-0E9E-4D94-BCAB-BD4B91FED2E4Q34951967-3C6829FB-9A76-4B5A-A27A-B1F4BD455DF8Q35003931-31BEC2F8-8E50-485B-8B0F-72979D72A58BQ35177864-2B7E252C-A70A-4C61-B368-E30780B6467CQ35191980-8F763069-C57E-4601-BCD0-086D69FF792EQ35557657-E64E8CF3-22F7-4427-9136-2DE65985EEE2Q35586865-3F7018A4-3D67-4C47-978D-4808D27B50D8Q36043731-4C16E0E8-3D95-449B-A79C-36BCF6FA4F8EQ36114395-B4F70535-BF8E-4C70-B63F-2E17F7E2B8ADQ36826984-3FB48ADC-1DC1-4FF3-81FF-31654505D931Q36906995-EFA06229-9057-4E69-BF4C-0DD4BB1C6DCDQ37025030-A5C75C49-A71A-4C88-9A68-F7F78237EF9DQ37220681-CC3318A9-EAE6-4D5B-AE3A-C2319758ADDBQ37256085-C5DCBED8-F85F-4FE0-B15F-F55398F013F6Q37265801-7F31B8F5-4AD6-4B34-A9F7-8E2EB0F75A6BQ37274832-709E91AD-E974-417D-960F-F14B9EA88F0DQ37349074-6CE45913-8936-4D41-9070-B237677C527BQ37867102-9F888744-21C1-42EC-ADAE-28086312B32F
P2860
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Safety and immunogenicity of a ...... el, Montanide ISA 720 or AS02.
@ast
Safety and immunogenicity of a ...... el, Montanide ISA 720 or AS02.
@en
type
label
Safety and immunogenicity of a ...... el, Montanide ISA 720 or AS02.
@ast
Safety and immunogenicity of a ...... el, Montanide ISA 720 or AS02.
@en
prefLabel
Safety and immunogenicity of a ...... el, Montanide ISA 720 or AS02.
@ast
Safety and immunogenicity of a ...... el, Montanide ISA 720 or AS02.
@en
P2093
P2860
P50
P1433
P1476
Safety and immunogenicity of a ...... el, Montanide ISA 720 or AS02.
@en
P2093
Alan Thomas
Andre van der Ven
Clemens H M Kocken
Ed Remarque
Erik de Jonge
Hildur Blythman
Karina Teelen
Marie Claude Dubois
Meta Roestenberg
P2860
P356
10.1371/JOURNAL.PONE.0003960
P407
P577
2008-12-18T00:00:00Z